Reneuron Group - Pisces-I Long-Term Data Published In The Lancet
Edison | Aug 05, 2016 07:59AM ET
Reneuron Group (LON:RQE) has announced the publication of long-term Phase I stroke clinical trial (PISCES-I) data in The Lancet. The data indicate improvements in neurological status and limb function compared with pre-treatment baseline performance within three months of treatment and throughout long-term follow up. Alongside this there were no cell-related or immunological adverse events across the four ascending dose levels in the study. This is positive as the data from the first stroke study continue to demonstrate safety, tolerability and functional improvement from the CTX cell therapy treatment. Investor focus is currently on the three-month readout of ReNeuron’s Phase II stroke disability study (PISCES-II) with its CTX cells, due in Q416. We maintain our rNPV at £249m.
Long-term Phase I data published – PISCES-I study
PISCES was a Phase I study, which treated 11 stroke-disabled patients with a range of doses of CTX cells (2m, 5m, 10m, 20m) injected into the damaged area of the brain. On safety, no cell-related or immunological adverse events were reported. In terms of treatment benefit, three out of 11 patients (~25%) had a one-point improvement after 24 months in the modified Rankin Score, regarded as clinically meaningful. Median NIHSS improved by two points, from 7 at baseline to 5 after 24 months (p=0.002). Please click here to read the Lancet publication.
To read the entire report Please click on the pdf File Below
Reneuron Group - Pisces-I Long-Term Data Published In The Lancet
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.